StreetInsider.com News Articles

Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum

Mon, 24 Aug 2026 12:20:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.

Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the

Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum

Mon, 24 Aug 2026 12:20:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.
Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the

Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum

Mon, 24 Aug 2026 12:20:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.
Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the

Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum

Mon, 24 Aug 2026 12:20:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.
Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the

Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum

Mon, 24 Aug 2026 12:20:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.
Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the

Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum

Mon, 24 Aug 2026 12:20:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.
Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the

Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum

Mon, 24 Aug 2026 12:20:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.
Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the

Aliko Scientific Provides a Financial Update Following the Publication of its FY 2025 Results and Reaffirms Its Business Momentum

Mon, 24 Aug 2026 12:20:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.
Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments

Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions

Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments

Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions

Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments

Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions

Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments

Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions

Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments

Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions

Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments

Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions

Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments

Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions

Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments

Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions

Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering

EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization

Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering

EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization

Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering

EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization

Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering

EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization

Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering

EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization

Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering

EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization

Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering

EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization

Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering

EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization

Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:
ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Hospitex signs deal for Uzbek cancer screening feasibility study

Thu, 23 Jul 2026 01:30:23 -0400

Aliko Scientific SA (Euronext Growth Paris: ALIKO), through its Italian subsidiary Hospitex International S.r.l., has signed an agreement with the Jizzakh branch of the Republican Scientific and Practical Centre specializing in oncology and radiology in Uzbekistan to conduct a feasibility study for a potential national urinary tract cancer screening program.

The study will assess the technical, operational, regulatory, financial, and organizational conditions required to potentially launch a pilot screening program based on Hospitex's Urine24 model. Work under the agreement has already begun.

The scope of the feasibility study includes operational workflow definition, laboratory and logistics assessment, legal and regulatory review, financial modeling,